Cervical Cancer Clinical Trial
Official title:
IT-system Development for Individualization of Cervix Cancer Screening and Implementation of New Strategies to Reach Non-attenders
The main purpose is to develop and test an IT-infrastructure to provide more individualized ways of inviting and reaching women who have not participated, despite having been invited with annual reminders, in cervix cancer screening program during a ten year period.
BACKGROUND Non-participation in the screening program is the main risk factor for cervical
cancer (Andrae et al JNCI, 2008). Therefore it is important to reduce barriers to screening
and facilitate participation in the screening program for cervical cancer. Offering
self-sampling kits for human papillomavirus (HPV) testing has been examined in several
research studies as a way to reach women who have not responded to screening invitations.
Results from a population-based, randomized study in western Sweden concluded that by
offering HPV self-sampling kits to screening non-attendees, 17% of cervical cancer cases
could be avoided. Offering self-sampling kits to women who have not attended screening in the
organized program, can lead to greater participation without substantial increases in the
overall health care costs. While there is a growing body of evidence supporting the use of
self-sampling, it is unclear how this strategy can be implemented effectively in the context
of an organized screening program. An alternative is to offer women the chance to speak with
a coordinating midwife who can answer questions and address concerns regarding screening. It
is unclear how the results of different research studies should be put into practical use
within an organized screening program. Currently, women who have not attended screening are
sent an annual reminder invitation. We want to examine whether these alternative strategies
(self-sampling and contact with a midwife) may work as well, or better, than current strategy
of reminder invitations to non-attenders.
AIM The aim of this randomized health services study is therefore both to test the
feasibility of providing alternative strategies instead of the customary reminder invitations
to women in Stockholm (so-called feasibility study, primary aim), and whether such strategies
will increase overall participation in screening (secondary aim).
STUDY DESIGN AND METHODOLOGY A new IT infrastructure for ordering a self-sampling kit has
been developed by LabMed, KI. This in conjunction with the screening database, will be used
to identify and invite women who are long-term non-participants in cervical screening. Women
who have not participated for ten years, despite annual reminder invitations, will be
identified and randomized to one of four strategies.
1. A validated HPV self-sampling kit will be sent directly to women with a study invitation
letter and instructions.
2. An invitation to order an HPV self-sampling kit through an online application will be
sent.
3. An invitation to call the coordinating midwife with questions and concerns regarding
screening will be sent.
4. The standard annual reminder invitation will be sent (control, routine practice)
Women who choose to participate will be sampled and monitored according to the standards of
care in the regional cancer screening program. HPV-positive women will be followed by
colposcopy and biopsy according to standard clinical guidelines. Women will be invited over
the course of 3 months. All letters will be printed in advance with pre-marked dates. Batches
will be sent out weekly and checked against changes in the population registry data (for
individuals that have moved, taken a smear, died, or unregistered, invitation letters will be
sorted out and those individuals marked in the database).
2 Notation and abbreviations
- PNR = person nummer, personal ID number 3 Study population 3.1 Inclusion criteria
- Women who have lived in Stockholm for the past 10 years and have been sent annual
reminder at least once per year for 10 years without attending screening.
Specific selection process:
Include women without an "H-prov" on record for the past 10 years Include women have actively
been sent a reminder invitation (invitation type=1) during 10 years time. In other words,
resident in Stockholm for the past 10 years.
Include women over the age of 33 3.2 Exclusion criteria Women who have opted out of the
screening program Hysterectomized Return to sender Changed PNR Women who are marked as
Expired=1. Women who have reason marked for being unregistered but are not marked as is
unregistered=1.
Women who are due to receive their reminder invitation in the next 3 months 4 Statistical
analyses Selection of the study population Randomization A random selection of 8000 women
will be chosen from all women meeting the study inclusion criteria.
These 8000 women will be randomized to the 4 study arms (age-stratified 30-50 and 51-60).
The selection of the study population and the randomization to study arms will be carried out
by Anna Stoltenberg, Statistician at RCC and outside of the study group 1.
Follow-up - study end date 2016-12-31
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06223308 -
A Study Evaluating the Safety and Efficacy of HB0028 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Terminated |
NCT03367871 -
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical Cancer
|
Phase 2 | |
Active, not recruiting |
NCT04537156 -
Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
|
Phase 3 | |
Recruiting |
NCT03668639 -
Safety and Antiemetic Efficacy of Akynzeo Plus Dexamethasone During Radiotherapy and Concomitant Weekly Cisplatin
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Withdrawn |
NCT04806945 -
A Phase III Study to Evaluate Efficacy and Safety of First-Line Treatment With HLX10 + Chemotherapy in Patients With Advanced Cervical Cancer
|
Phase 3 | |
Active, not recruiting |
NCT04185389 -
Long-Term Follow-Up of HPV FOCAL Participants
|
||
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT05120167 -
Strategies for Endocervical Canal Investigation in Women With Abnormal Screening Cytology and Negative Colposcopy
|
N/A | |
Recruiting |
NCT05483491 -
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
|
Phase 1 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Completed |
NCT05862844 -
Promise Women Project
|
N/A | |
Recruiting |
NCT04934982 -
Laparoscopic or Abdominal Radical Hysterectomy for Cervical Cancer(Stage IA1 With LVSI, IA2)
|
N/A | |
Recruiting |
NCT03876860 -
An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
|
N/A | |
Completed |
NCT03652077 -
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
|
Phase 1 | |
Completed |
NCT00543543 -
Broad Spectrum HPV (Human Papillomavirus) Vaccine Study in 16-to 26-Year-Old Women (V503-001)
|
Phase 3 | |
Terminated |
NCT04864782 -
QL1604 Plus Chemotherapy in Subjects With Stage IVB, Recurrent, or Metastatic Cervical Cancer
|
Phase 2/Phase 3 | |
Recruiting |
NCT04226313 -
Self-sampling for Non-attenders to Cervical Cancer Screening
|
N/A |